Marc Ciampi, MD
Nephrology · Waterbury, CTNPI 1366444135
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $9,625 of the $15,989 with a category attached, or 60.2%. Vifor Pharma, Inc. accounts for 64.7% of it on its own, with 34 other manufacturers making up the rest. Reporting peaked in 2021 at $5,859 and has fallen 87.0% since, to $761 in 2025.
Across 293 payments — averaging $54.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Vifor Pharma, Inc.$10K
- AstraZeneca$858
- Amgen$649
- Novo Nordisk$584
- Mallinckrodt Hospital Products Inc.$523
- Boehringer Ingelheim$369
- plus $3K from 29 others
What the payments were for
- Speaking & faculty fees$9,62560%
- Travel & lodging$600%
- Food & beverage$5,75336%
- Education$5513%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Vifor Pharma, Inc. | 25 | $10,338 |
| AstraZeneca(2 entities) | 34 | $858 |
| Amgen(2 entities) | 29 | $649 |
| Novo Nordisk | 44 | $584 |
| Mallinckrodt Hospital Products Inc. | 14 | $523 |
| Boehringer Ingelheim | 15 | $369 |
| Bayer | 11 | $297 |
| Novartis | 13 | $245 |
| Travere Therapeutics, Inc. | 16 | $242 |
| Akebia Therapeutics Inc | 10 | $210 |
| Otsuka America Pharmaceutical, Inc. | 10 | $196 |
| Sanofi | 9 | $185 |
| Fresenius USA Marketing, Inc. | 9 | $151 |
| Calliditas Therapeutics US Inc. | 7 | $144 |
| Xeris Pharmaceuticals, Inc. | 5 | $117 |
| Baxter Healthcare | 6 | $105 |
| OPKO Pharmaceuticals, LLC | 4 | $86 |
| Ultragenyx Pharmaceutical Inc. | 4 | $75 |
| Daiichi Sankyo Inc. | 3 | $56 |
| Arbor Pharmaceuticals, Inc. | 3 | $55 |
| GSK | 3 | $55 |
| AMAG Pharmaceuticals, Inc. | 3 | $54 |
| Aurinia Pharma U.S., Inc. | 2 | $53 |
| Pfizer | 2 | $53 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $42 |
| Cycle Pharmaceuticals Inc | 1 | $36 |
| Invivyd Inc | 1 | $33 |
| ANI Pharmaceuticals, Inc. | 1 | $31 |
| Ascendis Pharma Endocrinology Inc | 1 | $29 |
| Lilly USA, LLC | 1 | $25 |
| Ardelyx, Inc. | 1 | $22 |
| Johnson & Johnson | 1 | $21 |
| Mallinckrodt Enterprises LLC | 1 | $18 |
| Merck | 1 | $15 |
| Scpharmaceuticals Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$15,989 in reported general payments places this provider in the 85th percentile of 144 nephrology providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 251 | $205,373 |
| JardianceEmpagliflozin | 201 | $194,591 |
| AuryxiaFerric Citrate | 34 | $54,346 |
| OzempicSemaglutide | 42 | $52,248 |
| LokelmaSodium Zirconium Cyclosilicate | 61 | $38,573 |
| Teriparatide | 12 | $38,404 |
| EliquisApixaban | 17 | $18,349 |
| EntrestoSacubitril/Valsartan | 13 | $16,716 |
| Lanthanum Carbonate | 13 | $16,346 |
| Sevelamer Carbonate | 86 | $15,491 |
| EdarbiAzilsartan Medoxomil | 19 | $12,643 |
| TrulancePlecanatide | 13 | $7,135 |
| Amlodipine-Valsartan-HctzAmlodipine/Valsartan/Hcthiazid | 12 | $7,090 |
| DapagliflozinDapagliflozin Propanediol | 12 | $6,301 |
| Clonidine | 33 | $4,252 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Lokelma | $858 | $243,947312 claims |
| Boehringer IngelheimJardiance | $369 | $194,591201 claims |
| Akebia Therapeutics IncAuryxia | $210 | $54,34634 claims |
| Novo NordiskOzempic | $584 | $52,24842 claims |
| PfizerEliquis | $53 | $18,34917 claims |
| NovartisEntresto | $245 | $16,71613 claims |
| Arbor Pharmaceuticals, Inc.Edarbi | $55 | $12,64319 claims |
| ANI Pharmaceuticals, Inc.Valsartan | $31 | $1,66160 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 144 nephrology providers in Connecticut.
Other nephrology in Waterbury
- Sandeep TiyyaguraWaterbury$5K
- Andrew DonatiWaterbury$4K
- Anthony CusanoWaterbury$3K
- Robert AlpernNew Haven$4.9M
- Ari GellerBloomfield$209K
- Richard FormicaNew Haven$198K
- Stefan SomloNew Haven$111K
- James GavinTrumbull$103K
- Fredric FinkelsteinNew Haven$70K
- Justin BelcherNew Haven$59K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.